F
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.
Investor insights
Funding rounds participated in
$60M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2014
Funding rounds raised
Total raised
$60M
from investors over 1 rounds
F
Fusion Pharmaceuticals raised $60M on March 13, 2023